FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
The US Food and Drug Administration βon Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes.
Eli Lilly is slated to report third-quarter earnings and revenue, which will likely be fueled by its obesity drug Zepbound and diabetes counterpart Mounjaro.